On March 15, 2018 MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, reported that it will present three posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois at McCormick Place (Press release, MabVax, MAR 15, 2018, View Source [SID1234524812]). The first poster session features MVT-1075 (177Lu-CHX-A″-DTPA-HuMab5B1), the Company’s novel fully human antibody-based radioimmunotherapy (RIT) currently being evaluated in clinical development for the treatment of pancreatic cancer and other CA19-9 positive malignancies. The second presentation will feature preclinical investigations on the novel fully human antibody targeting the Thomsen-nouveau (Tn) and the sialyl Tn (sTn) cancer antigens which are highly overexpressed on ovarian and breast cancer tissues. The third poster features the Company’s immunoPET imaging agent MVT-2163 (89Zr-DFO-HuMab5B1), as a companion diagnostic for use in pancreatic cancer and CA19-9 positive malignancies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MabVax Therapeutics Logo (PRNewsfoto/MabVax Therapeutics Holdings, I)
Paul Maffuid, Ph.D., Executive Vice President of Research and Development of MabVax, stated, "We look forward to sharing the significant progress we have made through these clinical and preclinical studies that continue to establish our growing body of data supporting the development of MVT-1075 for the treatment of pancreatic cancer and other CA19-9 cancers, and our most advanced research program focused on the Tn and sTn cancer antigens."
Dr. Maffuid continued, "MVT-1075 potentially represents a more potent analog of our fully human HuMab-5B1 therapeutic antibody and establishing these safety and early response data bring us an important step closer in providing a much-needed treatment option for patients who have these devastating cancers. Equally important, our anti-Tn/sTn antibody program has made significant progress over the last few months and these data are the subject of partnering interest."
MabVax Abstracts and Poster Presentations
Sunday April 15, 2018 from 1:00 PM – 5:00 PM CDT:
Title: A fully human antibody binds Tn and sTn carbohydrate antigens specifically on serine residues, without need for polypeptide interaction
Session Location: Poster Section 43
Abstract Number: LB-002, Poster Board Number 2
Presenting Author: Jonah Rainey, Ph.D., Executive Director, Antibody Research MabVax Therapeutics
Tuesday April 17, 2018 from 8:00 AM – 12:00 PM CDT:
Title: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies
Session Location: McCormick Place South, Hall A, Poster Section 42
Abstract Number: CT140, Poster Board Number 23
Presenting Author: Paul Maffuid, Ph.D., Executive Vice President, Research & Development MabVax Therapeutics
Tuesday April 17, 2018 from 8:00 AM – 12:00 PM CDT:
Title: PEGylated Hyaluronidase Increases Tumor Uptake of 89Zr-DFO-HuMab-5B1 (MVT-2163) in a CA19-9 Positive Hyaluronan-Accumulating Pancreatic Cancer Model
Session Location: McCormick Place South, Hall A, Poster Section 1
Abstract Number: 3036, Poster Board Number 9
Co-presenting Authors: Paul Maffuid, Ph.D., Executive Vice President, Research & Development and Jonah Rainey, MabVax Therapeutics Executive Director, Antibody Research MabVax Therapeutics
About MVT-1075
MVT-1075 is a radioimmunotherapy product that combines established efficacy of radiation therapy with tumor specific targeting. It has the potential to deliver a more potent HuMab-5B1 based product. MVT-1075 uses small doses of the Company’s MVT-5873 antibody, coupled to a radioisotope to target pancreatic cancer cells and kill them.
About the HuMab-Tn Antibody Targeting Tn and sTn
HuMab-Tn is a fully human antibody derived from a patient vaccinated with a pool of cancer glycans, including Tn. The antibody has been affinity-matured and demonstrates highly selective Tn/sTn glycan binding. Further, the antibody recognizes a wide array of cancers, particularly ovarian and breast including approximately 90% of triple negative breast cancers tested.
About MVT-2163
MVT-1075 is an immunoPET imaging agent product that combines the established PET imaging capabilities of 89Zr with 5B1 tumor specific targeting. It has the potential to aid in identifying the best surgical treatment options for patients with pancreatic cancer and as a potential companion diagnostic with treatment options.